Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ACXP

Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACXP
DateTimeSourceHeadlineSymbolCompany
10/12/202400:00PR Newswire (US)Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsNASDAQ:ACXPAcurx Pharmaceuticals Inc
20/11/202423:01PR Newswire (US)Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:ACXPAcurx Pharmaceuticals Inc
20/11/202423:01PR Newswire (US)Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:ACXPAcurx Pharmaceuticals Inc
13/11/202423:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
13/11/202423:00PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
21/10/202422:00PR Newswire (US)Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/10/202423:00PR Newswire (US)Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor EngagementNASDAQ:ACXPAcurx Pharmaceuticals Inc
16/10/202423:00PR Newswire (US)Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024NASDAQ:ACXPAcurx Pharmaceuticals Inc
26/09/202421:00PR Newswire (US)Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 AnaloguesNASDAQ:ACXPAcurx Pharmaceuticals Inc
24/09/202421:00PR Newswire (US)Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile SymposiumNASDAQ:ACXPAcurx Pharmaceuticals Inc
26/08/202423:15GlobeNewswire Inc.New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PTNASDAQ:ACXPAcurx Pharmaceuticals Inc
26/08/202421:00PR Newswire (US)ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
19/08/202423:20GlobeNewswire Inc.New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PTNASDAQ:ACXPAcurx Pharmaceuticals Inc
09/08/202423:30GlobeNewswire Inc.New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ETNASDAQ:ACXPAcurx Pharmaceuticals Inc
09/08/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
09/08/202421:01PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/07/202421:00PR Newswire (US)USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut MicrobiomeNASDAQ:ACXPAcurx Pharmaceuticals Inc
16/07/202421:00PR Newswire (US)Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/07/202421:00PR Newswire (US)Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
19/06/202406:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACXPAcurx Pharmaceuticals Inc
19/06/202406:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACXPAcurx Pharmaceuticals Inc
18/06/202406:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
06/06/202423:30GlobeNewswire Inc.New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PTNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202423:00PR Newswire (US)Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202421:50IH Market NewsU.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices DropNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202421:00PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACXPAcurx Pharmaceuticals Inc
02/05/202421:00PR Newswire (US)Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
26/04/202400:12PR Newswire (US)Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACXP

Your Recent History

Delayed Upgrade Clock